文献速递类风湿关节炎

类风湿关节炎中Janus激酶(JAK)抑制剂的持续性:澳大利亚全国范围研究

Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study.
PubMed 文献 · Semin Arthritis Rheum · 2023-11-24

该回顾性观察研究基于澳大利亚Services Australia 10%药品福利计划(PBS)数据,纳入4521例2011至2021年间启动DMARD的类风湿关节炎患者,比较JAK抑制剂等药物的持续性。12个月持续性率乌帕替尼72%、巴瑞替尼61%、皮下TNFi 58%、托珠单抗55%、托法替布53%、阿巴西普49%。乌帕替尼和巴瑞替尼中位持续性未达到,所有药物均似有激素节约作用。

要点

  • 12个月持续性率乌帕替尼72%最高,巴瑞替尼61%次之,皮下TNFi 58%。
  • 乌帕替尼和巴瑞替尼中位持续性未达到,托法替布15.0个月。
  • 联合甲氨蝶呤或其他csDMARD时各b/tsDMARD持续性率更高。

核心结论

  • 在真实世界环境中,乌帕替尼持续性率最高,其次为巴瑞替尼,然后为TNFi治疗,联合治疗可改善持续性。
  • 所有药物似乎均有糖皮质激素节约作用。

研究设计与样本

  • 回顾性观察研究,纳入4521例类风湿关节炎患者(女性3181例[70.4%]),使用Services Australia 10%药品福利计划(PBS)数据集,年龄≥18岁,2011至2021年间启动DMARD。
  • 采用Kaplan-Meier分析估计持续性率,持续性定义为药物配发结束后出现6个月间隙。

主要发现

  • 12个月持续性率:乌帕替尼72%、巴瑞替尼61%、皮下肿瘤坏死因子-α抑制剂(TNFi)58%、托珠单抗55%、托法替布53%、阿巴西普49%。
  • 中位治疗持续性:乌帕替尼(n=574)和巴瑞替尼(n=553)未达到;托法替布15.0个月(95% CI 13.5-19.5)、TNFi 20.5个月(95% CI 19.0-22.4)、托珠单抗19.1个月(95% CI 17.9-23.6)、阿巴西普12.5个月(95% CI 10.4-14.9)。
  • 一线JAK抑制剂持续性率:乌帕替尼和巴瑞替尼68%、托法替布55%;TNFi 49%、阿巴西普55%、托珠单抗57%。
  • 二线治疗中乌帕替尼、TNFi和托珠单抗持续性率维持,巴瑞替尼降至59%、阿巴西普降至47%。
  • 每种b/tsDMARD与甲氨蝶呤或其他传统合成DMARD联合时持续性率更高。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare persistence of disease-modifying antirheumatic (DMARDs), with a focus on Janus kinase (JAK) inhibitors in Australian rheumatoid arthritis (RA) patients. METHODS: A retrospective observational study was conducted among 4,521 RA patients (females n=3,181 [70.4%]), using data from the Services Australia 10% Pharmaceuticals Benefits Scheme (PBS) dataset, aged ≥18 years and initiating a DMARD between 2011 to 2021. Kaplan-Meier analysis was used to estimate persistence rates, defined as occurrence of 6 months gap after the end of a drug dispensing. RESULTS: Twelve-month persistence rates were 72% for upadacitinib, 61% for baricitinib, 58% for subcutaneous tumor necrosis factor-alpha inhibitors (TNFi), 55% for tocilizumab, 53% for tofacitinib, and 49% for abatacept. Median treatment persistence was not reached for upadacitinib (n=574) and baricitinib (n=553); and was 15.0 months for tofacitinib (95% CI 13.5-19.5), 20.5 months for TNFi (95% CI 19.0-22.4), 19.1 months for tocilizumab (95% CI 17.9-23.6), and 12.5 months for abatacept (95% CI 10.4-14.9). Persistence rates on first-line JAK inhibitors were 68% for upadacitinib and baricitinib and 55% for tofacitinib, and 49% for TNFi, 55% for abatacept, and 57% for tocilizumab; rates were sustained for upadacitinib, TNFi, and tocilizumab but dropped to 59% for baricitinib and 47% for abatacept in the second-line treatment. For each b/tsDMARD, persistence rates were higher when combined with methotrexate or other conventional synthetic DMARDs. The median oral glucocorticoid dose decreased from 4.3 mg/day (range:0-40) to 2.3 mg/day (range:0-22) over 2 years. Changes were significant for all RA DMARDs, tofacitinib and baricitinib combined (1-2 years post initiation only), TNFi, abatacept, and tocilizumab. CONCLUSIONS: In a real-world setting, we showed highest persistence rates on upadacitinib, followed by baricitinib and then TNFi therapy and was improved by co-therapy. All agents appeared to be corticosteroid sparing.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Scheepers L, Yang Y, Chen YL, et al. Persistence of Janus-kinase (JAK) inhibitors in rheumatoid arthritis: Australia wide study. Semin Arthritis Rheum. 2023. PMID: 38029717. doi:10.1016/j.semarthrit.2023.152314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。